Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome: Findings From a Phase 1a Trial is a research paper published in American Journal of Kidney Diseases (2022). On theSindex it has a DataRank of 0.416. It has been cited 15 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.416
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →American College of Clinical Pharmacy Research Institute
Grant: UL1TR002489
American College of Clinical Pharmacy Research Institute
Grant: 5T32HL007148-43
The University of North Carolina at Chapel Hill North Carolina Translational and Clinical Sciences Institute
Grant: 550KR161709
NIDDK NIH HHS
Grant: L30 DK123764
NHLBI NIH HHS
Grant: T32 HL007149
National Institutes of Health
University of North Carolina
Merck
Novartis Pharmaceuticals Corporation
NHLBI
FWCI
1.36
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals